Dr. Tal Zaks, CEO of Exsilio Therapeutics and former CMO at Moderna, shares insights on navigating the biotech landscape, including his transition from the COVID-19 crisis to launching his mRNA startup. He discusses the integration of cutting-edge gene therapy technologies and the challenges of moving from academic concepts to therapeutic applications. Zaks emphasizes the importance of public education on mRNA safety, the dual role of medicine in healing and wellness, and the future potential of AI in biotech innovation.
54:04
forum Ask episode
web_stories AI Snips
view_agenda Chapters
menu_book Books
auto_awesome Transcript
info_circle Episode notes
volunteer_activism ADVICE
Funding Curiosity
Create a vision of your curiosity's potential value.
Show a path to concrete patient value to garner investment.
insights INSIGHT
FDA's Unique Approach
The FDA's in-depth analyses are unique and beneficial.
They focus on data, unlike other agencies that rely on applicants' proofs.
question_answer ANECDOTE
Exilio's Origin
Exilio Therapeutics explores jumping genes' potential for gene therapy.
Tal Zaks was intrigued by their idea of improving these elements for gene fixing.
Get the Snipd Podcast app to discover more snips from this episode
In 'Voltaire's Bastards,' John Ralston Saul dissects the contradictions, delusions, and illusions that have brought the world to the brink of confusion and crisis. The book examines the theology of power embedded in modern conceptions of Reason, arguing that the ascendancy of Reason has led to a world dominated by technocrats and elites who control knowledge and information. Saul critiques the hypocrisies of democracy, the obsession with efficiency and expertise, and the failure of modern societies to address critical issues such as war, economics, and environmental degradation. The book is a call to rethink traditional institutions and notions as we move into a new era[3][4][5].
Dr. Tal Zaks is back, along with Advancing RNA's Anna Rose Welch, for part 2 of "Story Time With Tal." On this week's episode, we turn from his time navigating medical affairs as CMO at Moderna during the COVID 19 pandemic to learn about his latest venture, an mRNA startup called Exsilio Therapeutics. We cover the foundational aspects of the company's start, from the science it's developing, who's been recruited to the team, and how Exsilio charted its way to an $82 million Series A co-led by Novartis Venture Fund and Delos Capital, with participation from OrbiMed, Insight Partners, J.P. Morgan Life Sciences Private Capital, CRISPR Therapeutics, Innovation Endeavors, Invus, Arc Ventures, and Deep Insight.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
Business Of Biotech 